Hereditary ATTR (HATTR) Amyloidosis
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein in the body's organs and tissues. Hereditary ATTR (hATTR) amyloidosis is the most common form of ATTR; nevertheless, it is a very rare disease.
As per DelveInsight, Hereditary ATTR Amyloidosis diagnosed prevalence was recorded to be the highest in the United States, with a 10.2% growth rate.
Pharma companies like Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, and many others are accelerating the Hereditary transthyretin amyloidosis market forward.
The newsletter is aimed to help its readers and clients to gain a perspective on the latest trends in the hATTR Market, its epidemiology, and the role of mutations that form the underlying cause of the disease.
The newsletter offers a peek into the vast repository DelveInsight hosts providing pharma market research reports with the pipeline activity, key companies developing drugs, research and innovative approaches in the field, and latest collaborations, and licensing deals on the news front.
Download the newsletter by filling up an easy form to the right and subscribe to our emailer list for more such bespoke insights delivered right into your inbox.
Stay in the loop.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Support from International organizations
